Antimicrobial Stewardship & Empiric Regimens

Bacterial peptidoglycan synthesis proceeds across cytosolic, membrane-transport, and extracellular cross-linking stages, each targeted by distinct bactericidal antibiotics. Within the bacterial cytoplasm, fosfomycin irreversibly inhibits enolpyruvyl transferase (MurA), preventing the condensation of phosphoenolpyruvate with UDP-N-acetylglucosamine (used as a single oral dose for uncomplicated E. coli cystitis), while D-cycloserine competitively inhibits alanine racemase and D-Ala-D-Ala ligase. Once the peptidoglycan precursor is synthesized, the lipid carrier bactoprenol (undecaprenyl pyrophosphate) transports the subunit across the cytoplasmic membrane; topical bacitracin inhibits the dephosphorylation and recycling of bactoprenol. Extracellularly, glycopeptides (vancomycin, telavancin, dalbavancin) bind non-covalently via five hydrogen bonds to the terminal D-Alanyl-D-Alanine pentapeptide stem, sterically blocking transglycosylation and transpeptidation in Gram-positive bacteria (intrinsic resistance in Gram-negatives because large glycopeptides cannot penetrate outer-membrane porins; acquired resistance in VRE and VRSA via vanA replacement of D-Ala-D-Ala with D-Ala-D-Lactate). Finally, β-lactams act as structural analogs of D-Ala-D-Ala that covalently acylate the catalytic serine residue of penicillin-binding proteins (PBPs / transpeptidases).

Optimizing antimicrobial dosing regimens requires distinguishing pharmacodynamic killing curves. Time-dependent bactericidal agents—principally all β-lactams (penicillins, cephalosporins, carbapenems, aztreonam) and vancomycin (AUC/MIC-driven)—maximize bacterial eradication when free serum drug concentrations remain above the minimum inhibitory concentration (fT > MIC) for 40% to 70% of the dosing interval; this explains why piperacillin-tazobactam and meropenem are frequently administered via extended 3- to 4-hour infusions in critically ill ICU patients. Conversely, concentration-dependent bactericidal agents—notably aminoglycosides (gentamicin, tobramycin, amikacin), fluoroquinolones (ciprofloxacin, levofloxacin), daptomycin, and metronidazole—achieve maximal killing when the peak serum concentration to MIC ratio (C_max/MIC) is maximized, and exhibit a prolonged post-antibiotic effect (PAE) in which bacterial regrowth remains suppressed even after serum drug levels fall below the MIC. This allows once-daily high-dose aminoglycoside consolidation, which saturates bacterial ribosomal killing while minimizing saturable renal proximal tubular brush-border megalin uptake (reducing nephrotoxicity) and cochlear hair cell accumulation (ototoxicity).

Empiric pneumonia therapy depends on whether the infection was acquired in the community or after ≥48 hours of hospitalization/mechanical ventilation. For outpatient CAP in healthy adults without cardiopulmonary comorbidities or recent antibiotic use (within 90 days), first-line options are high-dose amoxicillin (1 g TID), doxycycline, or a macrolide (azithromycin, only if local pneumococcal macrolide resistance is <25%). For outpatient CAP with comorbidities (COPD, heart failure, diabetes, CKD, alcoholism) or inpatient non-ICU CAP, regimens must cover both typical beta-lactamase-producing bacteria (S. pneumoniae, H. influenzae, M. catarrhalis) and intracellular atypicals (Mycoplasma, Legionella, Chlamydia) using either a β-lactam (amoxicillin-clavulanate outpatient; ceftriaxone or ampicillin-sulbactam inpatient) PLUS a macrolide (azithromycin) or doxycycline, OR respiratory fluoroquinolone monotherapy (levofloxacin or moxifloxacin—never ciprofloxacin, which lacks reliable pneumococcal coverage). In contrast, hospital-acquired (HAP) and ventilator-associated pneumonia (VAP) require immediate empiric coverage of both Pseudomonas aeruginosa (piperacillin-tazobactam, cefepime, or meropenem) and MRSA (vancomycin or linezolid—never daptomycin, which is inactivated by pulmonary surfactant).

Three time-critical infectious emergencies require immediate empiric antibiotic administration within 60 minutes of presentation. In acute bacterial meningitis, empiric regimens are stratified by age and cell-mediated immunity: neonates (<1 month) receive ampicillin (for Listeria and Group B Streptococcus) plus cefotaxime or gentamicin (for E. coli)—avoiding ceftriaxone in neonates due to albumin bilirubin displacement (kernicterus) and biliary calcium-ceftriaxone precipitation; children and adults (1 month to 50 years) receive vancomycin (for penicillin-resistant S. pneumoniae) plus ceftriaxone (for N. meningitidis and H. influenzae) alongside IV dexamethasone administered before or with the first antibiotic dose to prevent pneumococcal sensorineural hearing loss and neurologic sequelae; and adults >50 years, pregnant patients, alcoholics, or immunocompromised hosts require adding ampicillin to vancomycin + ceftriaxone to cover Listeria monocytogenes. In febrile neutropenia (ANC <500/mm³ with single oral temperature ≥38.3°C), immediate monotherapy with an anti-pseudomonal beta-lactam (cefepime, meropenem, or piperacillin-tazobactam) is mandatory, adding vancomycin only for suspected catheter infection, cellulitis, pneumonia, or shock.

Prokaryotic 70S ribosomes (composed of 30S and 50S subunits, distinct from eukaryotic 80S cytoplasmic ribosomes) are targeted by classes recalled via "Buy AT 30, CCEL at 50". On the 30S subunit, aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin) are uniquely bactericidal: they require oxygen-dependent active electron transport to enter bacteria (making them completely ineffective against obligate anaerobes, though synergistic with cell-wall active beta-lactams or vancomycin against Enterococcus and infective endocarditis), bind the 30S initiation complex, and induce mRNA codon misreading. Tetracyclines (doxycycline, minocycline, demeclocycline) and glycylcyclines (tigecycline) bind the 30S A-site to sterically block aminoacyl-tRNA attachment; oral absorption is chelated by divalent/trivalent cations (Ca²⁺, Mg²⁺, Fe²⁺, Al³⁺), doxycycline is uniquely excreted in feces (safe in renal failure), and all tetracyclines cause photosensitivity and permanent tooth enamel discoloration/bone growth inhibition in children <8 years and pregnancy. On the 50S subunit, chloramphenicol inhibits peptidyltransferase (causing dose-independent aplastic anemia and neonatal Gray Baby Syndrome from immature hepatic UDP-glucuronosyltransferase), macrolides and clindamycin block polypeptide exit-tunnel translocation (sharing MLS_B 23S rRNA methylation resistance), and linezolid binds 23S rRNA at the 50S interface to prevent 70S initiation complex formation (causing thrombocytopenia/bone marrow suppression after >2 weeks and weak MAO inhibition precipitating serotonin syndrome with SSRIs).

Because bacteria cannot absorb exogenous folic acid and must synthesize tetrahydrofolate de novo from para-aminobenzoic acid (PABA), sequential enzymatic blockade produces bactericidal synergy. Sulfonamides (sulfamethoxazole, sulfadiazine, dapsone) competitively inhibit dihydropteroate synthase, while trimethoprim (and pyrimethamine) inhibits bacterial dihydrofolate reductase (DHFR)—depleting purine and thymidine nucleotides. Trimethoprim-sulfamethoxazole (TMP-SMX) treats uncomplicated UTIs, Nocardia, Listeria (in penicillin-allergic patients), and Pneumocystis jirovecii pneumonia (prophylaxis initiated in HIV when CD4 <200 cells/mm³), but causes sulfa hypersensitivity (Stevens-Johnson syndrome), hemolysis in G6PD deficiency, megaloblastic anemia (rescued with leucovorin), neonatal kernicterus (albumin bilirubin displacement), and ENaC blockade hyperkalemia + benign creatinine elevation (competitive tubular secretion blockade). Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) inhibit prokaryotic topoisomerase II (DNA gyrase) and topoisomerase IV, carrying boxed warnings for tendinopathy/Achilles tendon rupture (especially with corticosteroids or age >60), peripheral neuropathy, aortic aneurysm dissection, QT prolongation, and pediatric epiphyseal cartilage damage. Daptomycin inserts calcium-dependent lipopeptide tails into Gram-positive cell membranes to cause rapid K⁺ efflux and depolarization (treating MRSA bacteremia/endocarditis and VRE, monitored with weekly CPK for myopathy/rhabdomyolysis, and inactivated by pulmonary surfactant).

Active Mycobacterium tuberculosis infection requires initial four-drug therapy with Rifampin, Isoniazid, Pyrazinamide, and Ethambutol (RIPE) for 2 months followed by Isoniazid plus Rifampin for 4 months. Isoniazid (INH) is a prodrug activated by mycobacterial catalase-peroxidase (encoded by katG) into a reactive species that inhibits enoyl-ACP reductase (encoded by inhA), halting mycolic acid synthesis. INH is metabolized by hepatic N-acetyltransferase 2 (NAT2, exhibiting bimodal fast vs. slow acetylator genetics); it causes hepatotoxicity, anti-histone drug-induced lupus, and competitive inhibition of pyridoxal phosphokinase + enhanced pyridoxine excretion—mandating universal co-administration of vitamin B₆ (pyridoxine) to prevent peripheral neuropathy, sideroblastic anemia, and refractory GABA-depletion seizures. Rifampin binds the β-subunit of bacterial DNA-dependent RNA polymerase (rpoB) to block transcription initiation; it turns sweat, tears, and urine harmless red-orange and is the most potent board-tested CYP450 (CYP3A4/2C9) inducer (Whereas rifabutin is substituted in HIV patients on protease inhibitors or integrase inhibitors due to markedly weaker CYP3A4 induction). Pyrazinamide (activated by pyrazinamidase pncA inside acidic macrophage phagolysosomes) causes hyperuricemia and gout, while ethambutol inhibits arabinosyltransferase (embB, blocking arabinogalactan cell wall polymerization) and causes dose-dependent retrobulbar optic neuritis presenting with red-green color blindness and central scotoma.

Fungal cell membranes contain ergosterol rather than mammalian cholesterol, and fungal cell walls contain β-(1,3)-D-glucan. Amphotericin B (a polyene) directly binds membrane ergosterol to assemble transmembrane ion-leaking pores; it remains the gold standard for life-threatening disseminated mycoses (cryptococcal meningitis paired with flucytosine, mucormycosis, severe histoplasmosis/blastomycosis), but causes acute infusion reactions ("shake and bake" fever/rigors), cumulative dose-dependent nephrotoxicity (afferent vasoconstriction and distal renal tubular acidosis with severe K⁺ and Mg²⁺ wasting, mitigated by liposomal formulations and saline hydration), and normocytic anemia. Azoles (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole) inhibit fungal cytochrome P450 14α-demethylase, blocking lanosterol-to-ergosterol conversion and inhibiting human hepatic CYP450 enzymes (voriconazole is first-line for invasive Aspergillus and causes transient visual hallucinations/photopsia). Echinocandins (-fungins: caspofungin, micafungin, anidulafungin) inhibit β-(1,3)-D-glucan synthase (effective against invasive Candida and salvage Aspergillus, completely ineffective against Cryptococcus). Among antivirals, acyclovir/valacyclovir (requiring HSV/VZV thymidine kinase) and ganciclovir/valganciclovir (requiring CMV UL97 kinase; dose-limiting toxicity: bone marrow neutropenia) inhibit viral DNA polymerase via obligate chain termination, whereas foscarnet (a pyrophosphate analog) and cidofovir bypass viral kinases directly to treat kinase-mutated resistant strains (foscarnet chelates ionized Ca²⁺ and Mg²⁺, precipitating hypocalcemic tetany and seizures).

Across the five generations of cephalosporins, Gram-negative outer-membrane penetration and β-lactamase stability progressively expand while Gram-positive staphylococcal activitygenerally tapers until the 5th generation—and Listeria monocytogenes, Atypicals (Mycoplasma, Legionella, Chlamydia), MRSA (except 5th-gen ceftaroline), and Enterococci ("LAME") remain intrinsically resistant to 1st–4th generation cephalosporins. 1st Generation (cefazolin, cephalexin — "PEcK") covers MSSA, streptococci, and Proteus, E. coli, Klebsiella (surgical prophylaxis and skin cellulitis). 2nd Generation (cefuroxime, cefoxitin, cefotetan — "HEN PEcK") adds Haemophilus, Enterobacter, Neisseria, and Bacteroides fragilis (cefoxitin/cefotetan for pelvic/abdominal prophylaxis). 3rd Generation splits into ceftriaxone (CNS penetration for meningitis, single-dose IM for gonorrhea, biliary clearance) and ceftazidime (potent Pseudomonas coverage). 4th Generation (cefepime) is a zwitterion with broad Gram-positive (MSSA/streptococci) and Pseudomonas activity. 5th Generation (ceftaroline) uniquely binds PBP2a (encoded by mecA) to eradicate MRSA. Carbapenems (imipenem-cilastatin, meropenem, doripenem, ertapenem—note ertapenem lacks Pseudomonas and Acinetobacter coverage) are the drugs of choice for ESBL-producing Enterobacterales; imipenem is co-formulated with cilastatin to inhibit renal proximal tubular dehydropeptidase-I and lowers the seizure threshold via GABA_A antagonism. Aztreonam (a monobactam) binds only Gram-negative aerobic PBP3 (including Pseudomonas) and exhibits zero cross-allergenicity in IgE-mediated penicillin anaphylaxis (except shared R1 side-chain allergy with ceftazidime).

Antiparasitic selection follows a disciplined organism-to-mechanism matrix. Against nematodes (roundworms: Enterobius, Ascaris, Ancylostoma/Necator, Strongyloides, Trichinella), benzimidazoles (albendazole, mebendazole) bind parasite β-tubulin to inhibit microtubule polymerization and immobilize glucose uptake (albendazole is also the medical therapy of choice for cystic neurocysticercosis and hepatic Echinococcus granulosus hydatid cysts, where surgical aspiration without pretreatment risks fatal anaphylaxis). Pyrantel pamoate acts as a depolarizing neuromuscular nicotinic agonist causing spastic paralysis of Enterobius and hookworms. Ivermectin activates glutamate-gated Cl⁻ channels to hyperpolarize and paralyze Onchocerca volvulus (river blindness), Strongyloides stercoralis, and cutaneous Sarcoptes scabiei. Against trematodes (flukes: Schistosoma, Clonorchis, Paragonimus) and cestodes (tapeworms: Taenia solium, Diphyllobothrium latum), praziquantel increases tegumental Ca²⁺ permeability to induce tetanic contraction and vacuolization. In malaria, chloroquine blocks plasmodial heme polymerase in the food vacuole (causing toxic ferriprotoporphyrin IX accumulation; resistance mediated by PfCRT efflux pumps requires artemether-lumefantrine or atovaquone-proguanil), while dormant hepatic hypnozoites of Plasmodium vivax and Plasmodium ovale require radical cure with primaquine (strictly after confirming normal G6PD activity to prevent Heinz-body hemolytic anemia).

Active Mycobacterium tuberculosis requires four-drug RIPE therapy (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) for a 2-month intensive phase followed by 4 months of Rifampin + Isoniazid. Isoniazid (INH) is a prodrug activated by bacterial catalase-peroxidase (encoded by katG) that inhibits InhA (enoyl-ACP reductase), halting mycolic acid synthesis. INH undergoes hepatic N-acetylation via polymorphic NAT2 (slow acetylators develop drug-induced SLE) and competitively depletes pyridoxal phosphate (Vitamin B₆) by forming hydrazones and inhibiting pyridoxine phosphokinase—mandating routine pyridoxine (B₆) co-administration to prevent peripheral neuropathy, sideroblastic anemia (ringed sideroblasts via ALAS2 cofactor depletion), and refractory status epilepticus (treated specifically with IV pyridoxine).

Rifampin (and rifabutin) binds the rpoB beta-subunit of bacterial DNA-dependent RNA polymerase, blocking transcription initiation. It causes harmless red-orange discoloration of urine, tears, and sweat, and acts as the prototype potent CYP450 inducer (accelerating clearance of HIV protease inhibitors, warfarin, oral contraceptives, and methadone; rifabutin is substituted in HIV patients because it induces CYP3A4 far less). Pyrazinamide is converted by pyrazinamidase (pncA) to pyrazinoic acid inside acidic phagolysosomes (pH <5.5), causing hyperuricemia/gout and hepatotoxicity. Ethambutol inhibits arabinosyltransferase (embB), blocking arabinogalactan polymerization and causing dose-dependent retrobulbar optic neuritis (loss of red-green color vision and central scotoma). For leprosy (M. leprae), tuberculoid disease is treated with dapsone + rifampin for 6–12 months, whereas lepromatous leprosy requires adding clofazimine for 12–24 months (dapsone causes G6PD hemolysis and methemoglobinemia; thalidomide or corticosteroids treat erythema nodosum leprosum).

Fungal cell membranes rely on ergosterol rather than cholesterol. Amphotericin B (polyene) binds directly to ergosterol, forming transmembrane pores that cause lethal electrolyte leakage (K⁺, Mg²⁺). It remains the gold standard for life-threatening disseminated mycoses (cryptococcal meningitis [paired with flucytosine, which is converted by fungal cytosine deaminase to 5-FU], mucormycosis, severe histoplasmosis/blastomycosis/coccidioidomycosis). Signature toxicities include "shake and bake" infusion reactions, afferent arteriolar vasoconstriction + distal renal tubular acidosis with severe hypokalemia and hypomagnesemia (mitigated by liposomal formulations and IV saline hydration). Nystatin acts by the same pore-forming mechanism but is too toxic for IV use—administered as "swish and swallow" for oral candidiasis or topically for diaper dermatitis.

Azoles (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole) inhibit fungal lanosterol 14α-demethylase (a CYP450 enzyme), blocking ergosterol synthesis. All azoles inhibit human hepatic CYP450 enzymes and cause hepatotoxicity/QT prolongation (except isavuconazole, which shortens QT). Key clinical pairings: Fluconazole penetrates CSF seamlessly (cryptococcal meningitis maintenance, candidemia); Itraconazole treats mild-to-moderate endemic dimorphic fungi (Histoplasma, Blastomyces, Sporothrix) and requires gastric acid for absorption; Voriconazole is first-line for invasive pulmonary aspergillosis (causes transient visual hallucinations/blurring and photosensitivity); Posaconazole/Isavuconazole cover Mucorales (mucormycosis). Echinocandins (micafungin, caspofungin, anidulafungin) inhibit cell-wall beta-1,3-D-glucan synthase, making them first-line for invasive candidemia and salvage therapy for aspergillosis (ineffective against Cryptococcus). Terbinafine inhibits fungal squalene epoxidase, accumulating toxic squalene to cure dermatophyte onychomycosis (oral, hepatotoxic), while griseofulvin binds keratin and disrupts fungal microtubule mitotic spindles.

Acyclovir, Valacyclovir, and Famciclovir are guanosine analogs used for HSV-1, HSV-2, and VZV (herpes zoster/varicella). They require monophosphorylation by viral thymidine kinase (TK) before host cellular kinases convert them to acyclovir triphosphate, which competitively inhibits viral DNA polymerase and acts as an obligate chain terminator (lacking a 3'-OH group). Resistance arises via mutated or deficient viral thymidine kinase. High-dose IV acyclovir (for HSV encephalitis) precipitates as needle-shaped crystals in renal tubules (crystalline nephropathy), prevented by vigorous IV crystalloid hydration.

Ganciclovir (and oral prodrug Valganciclovir) treats Cytomegalovirus (CMV) retinitis, colitis, esophagitis, and post-transplant viremia. Because CMV lacks thymidine kinase, ganciclovir is monophosphorylated by the CMV-encoded UL97 protein kinase and inhibits UL54 viral DNA polymerase. Its major dose-limiting toxicity is severe myelosuppression (neutropenia and thrombocytopenia), particularly when co-administered with zidovudine or mycophenolate.

Foscarnet is a structural analog of inorganic pyrophosphate that directly chelates the pyrophosphate-binding site of viral DNA polymerase (and HIV reverse transcriptase) without requiring any viral kinase activation. Consequently, foscarnet is the treatment of choice for TK-deficient acyclovir-resistant HSV/VZV and UL97-mutant ganciclovir-resistant CMV. Foscarnet causes severe nephrotoxicity and chelates divalent cations in plasma, precipitating symptomatic hypocalcemia, hypomagnesemia, and hypokalemia (presenting with perioral paresthesias, Chvostek/Trousseau signs, and seizures). Cidofovir is an acyclic nucleoside phosphonate (already monophosphorylated, bypassing viral kinases) that must be co-administered with probenecid and IV saline to block OAT1-mediated proximal tubular uptake and prevent severe nephrotoxicity.

First-line initial HIV-1 antiretroviral therapy (ART) consists of an Integrase Strand Transfer Inhibitor (INSTI: bictegravir, dolutegravir) combined with two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs: tenofovir [TAF or TDF] + emtricitabine or abacavir + lamivudine). NRTIs competitively inhibit HIV reverse transcriptase and terminate DNA chains after host phosphorylation: Abacavir requires screening for HLA-B*57:01 prior to initiation to prevent fatal hypersensitivity syndrome; Tenofovir disoproxil fumarate (TDF) causes proximal renal tubular dysfunction (Fanconi syndrome) and osteopenia (whereas tenofovir alafenamide [TAF] reduces renal/bone toxicity); and Zidovudine (AZT) causes megaloblastic anemia/neutropenia and mitochondrial myopathy. NNRTIs (efavirenz, rilpivirine, doravirine) bind an allosteric hydrophobic pocket on HIV-1 reverse transcriptase without requiring phosphorylation (ineffective against HIV-2; efavirenz causes vivid dreams and CNS neuropsychiatric toxicity). Protease Inhibitors (darunavir, atazanavir, lopinavir—boosted by CYP3A4 inhibitor ritonavir or cobicistat) block HIV-1 protease cleavage of the pol/gag polyprotein into mature virions; they cause insulin resistance, dyslipidemia, lipodystrophy, and class-specific adverse effects (atazanavir inhibits UGT1A1 causing unconjugated hyperbilirubinemia; indinavir causes radiolucent nephrolithiasis). Entry inhibitors include maraviroc (blocks host CCR5 coreceptor; requires tropism assay) and enfuvirtide (binds viral gp41 to block membrane fusion).

Direct-Acting Antivirals (DAAs) cure chronic Hepatitis C in >95% of patients by targeting three viral proteins: NS5B RNA-dependent RNA polymerase (-buvir: sofosbuvir), NS5A replication complex (-asvir: ledipasvir, velpatasvir, pibrentasvir), and NS3/4A serine protease (-previr: glecaprevir, grazoprevir). For Influenza A and B, oseltamivir and zanamivir inhibit viral neuraminidase (preventing cleavage of terminal sialic acid residues and trapping progeny virions on the host cell surface), whereas baloxavir marboxil inhibits the viral cap-dependent endonuclease (blocking "cap snatching" of host mRNA primers).